View Item 

Show simple item record

Cysteinyl Leukotriene Levels in Esophageal Mucosal Biopsies of Children with Eosinophilic Inflammation: Are They All the Same?

dc.contributor.authorGupta, Sandeep K.en_US
dc.contributor.authorPeters-Golden, Marc L.en_US
dc.contributor.authorFitzgerald, Joseph F.en_US
dc.contributor.authorCroffie, Joseph M.en_US
dc.contributor.authorPfefferkorn, Marian D.en_US
dc.contributor.authorMolleston, Jean P.en_US
dc.contributor.authorCorkins, Mark R.en_US
dc.contributor.authorLim, Joel R.en_US
dc.date.accessioned2010-06-01T22:30:46Z
dc.date.available2010-06-01T22:30:46Z
dc.date.issued2006-05en_US
dc.identifier.citationGupta, Sandeep K.; Peters-Golden, Marc; Fitzgerald, Joseph F.; Croffie, Joseph M.; Pfefferkorn, Marian D.; Molleston, Jean P.; Corkins, Mark R.; Lim, Joel R. (2006). "Cysteinyl Leukotriene Levels in Esophageal Mucosal Biopsies of Children with Eosinophilic Inflammation: Are They All the Same?." The American Journal of Gastroenterology 101(5): 1125-1128. <http://hdl.handle.net/2027.42/75498>en_US
dc.identifier.issn0002-9270en_US
dc.identifier.issn1572-0241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75498
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16573772&dopt=citationen_US
dc.format.extent178602 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights2006 by Am. Coll. of Gastroenterologyen_US
dc.titleCysteinyl Leukotriene Levels in Esophageal Mucosal Biopsies of Children with Eosinophilic Inflammation: Are They All the Same?en_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDivision of Pediatric Gastroenterology, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indianaen_US
dc.identifier.pmid16573772en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75498/1/j.1572-0241.2006.00557.x.pdf
dc.identifier.doi10.1111/j.1572-0241.2006.00557.xen_US
dc.identifier.sourceThe American Journal of Gastroenterologyen_US
dc.identifier.citedreferenceLevine MS, Saul SH. Idiopathic eosinophilic esophagitis: How common is it? Radiology 1993; 186: 631 – 2.en_US
dc.identifier.citedreferenceKelly KJ, Lazenby AJ, Rowe PC, et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: Improvement with an amino acid-based formula. Gastroenterology 1995; 109: 1503 – 12.en_US
dc.identifier.citedreferenceStraumann A, Spichtin HP, Grize L, et al. Natural history of primary eosinophilic esophagitis: A follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003; 125: 1660 – 9.en_US
dc.identifier.citedreferenceSteiner SJ, Gupta SK, Croffie JM, et al. Correlation between number of eosinophils and reflux index on same day esophageal biopsy and 24-hour pH monitoring. Am J Gastroenterol 2004; 99: 801 – 5.en_US
dc.identifier.citedreferenceGupta SK, Fitzgerald JF, Chong SK, et al. Vertical lines in distal esophageal mucosa (VLEM): A true endoscopic manifestation of esophagitis in children? Gastrointest Endosc 1997; 45: 485 – 9.en_US
dc.identifier.citedreferenceLim JR, Gupta SK, Fitzgerald JF, et al. White specks in esophageal mucosa (WSEM): An endoscopic manifestation of non-reflux eosinophilic esophagitis (EE) in children. Gastrointest Endosc 2004; 59: 835 – 8.en_US
dc.identifier.citedreferenceLiacouras CA, Wenner WJ, Brown K, et al. Primary eosinophilic esophagitis in children: Successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr 1998; 26: 380 – 5.en_US
dc.identifier.citedreferenceFaubion WA Jr, Perrault J, Burgart LJ, et al. Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr 1998; 27: 90 – 3.en_US
dc.identifier.citedreferenceGupta SK, Fitzgerald JF, Davis MM, et al. Treatment of allergic eosinophilic esophagitis (AEE) with oral prednisone (P) and swallowed fluticasone (F): A randomized, prospective study in children. Gastroenterology 2003; 124: A19.en_US
dc.identifier.citedreferenceMarkowitz JE, Spergel JM, Ruchelli E, et al. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 2003; 98: 777 – 82.en_US
dc.identifier.citedreferenceWhelan GJ, Blake K, Kissoon N, et al. Effect of montelukast on time-course of exhaled nitric oxide in asthma: Influence of LTC 4 synthase A −444 C polymorphism. Pediatr Pulmonol 2003; 36: 413 – 20.en_US
dc.identifier.citedreferenceBisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics 2001; 107: 381 – 90.en_US
dc.identifier.citedreferenceSing JT Jr, Jones BA. Leukotriene receptor antagonist as a new mode of therapy for eosinophilic gastroenteritis. Am J Gastroenterol 2001; 96: S245.en_US
dc.identifier.citedreferenceVanderhoof JA, Young RJ, Hanner TL, et al. Montelukast: Use in pediatric patients with eosinophilic gastrointestinal disease. J Pediatr Gastroenterol Nutr 2003; 36: 293 – 4.en_US
dc.identifier.citedreferenceAttwood SEA, Lewis CJ, Bronder CS, et al. Eosinophilic oesophagitis: A novel treatment using montelukast. Gut 2003; 52: 181 – 5.en_US
dc.identifier.citedreferenceWilborn J, Crofford LJ, Burdick MD, et al. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995; 95: 1861 – 8.en_US
dc.identifier.citedreferenceSalvi SS, Krishna MT, Sampson AP, et al. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001; 119: 1533 – 46.en_US
dc.identifier.citedreferenceSchwartz DA, Pardi DS, Murray JA. Use of montelukast as steroid-sparing agent for recurrent eosinophilic gastroenteritis. Dig Dis Sci 2001; 46: 1787 – 90.en_US
dc.identifier.citedreferenceRobinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: A randomised double-blind placebo-controlled trial. Lancet 2001; 357: 2007 – 11.en_US
dc.identifier.citedreferenceSmith LJ. Newer asthma therapies. Ann Intern Med 1999; 130: 531 – 2.en_US
dc.identifier.citedreferenceFriesen CA, Kearns GL, Andre L, et al. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr 2004; 38: 343 – 51.en_US
dc.identifier.citedreferenceMalmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med 1999; 130: 487 – 95.en_US
dc.identifier.citedreferenceDaikh BE, Ryan CK, Schwartz RH. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture. Ann Allergy Asthma Immunol 2003; 90: 23 – 7.en_US
dc.identifier.citedreferenceGupta SK, Fitzgerald JF, Chong SKF, et al. Long term outcome of vertical lines in the (distal) esophageal mucosa (VLEM) and eosinophilic esophagitis: A prospective study. Gastrointest Endosc 1996; 43: 327.en_US
dc.identifier.citedreferenceWilborn J, Bailie M, Coffey M, et al. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996; 97: 1827 – 36.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1572-0241.2006.00557.x.pdf
Size:
174.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.